title: Cost-effectiveness analysis of a universal rotavirus immunization program in Japan.
abstract: In anticipation of the imminent licensure of rotavirus vaccine, we evaluated the cost-effectiveness of rotavirus vaccine in Japan by taking into account the considerable variations in the incidence of rotavirus-associated hospitalizations previously reported in the literature. We assumed that the variation was due to local differences in healthcare utilization practices rather than a true difference in the incidence of severe rotavirus gastroenteritis. Thus, a Markov model was constructed such that the sum of rotavirus-associated hospitalizations and outpatient visits was set a constant value of 129 cases per 1,000 child-years. We calculated the direct medical cost, the indirect cost, and the quality-adjusted life year (QALY) loss in children aged less than 5 years. For the base case scenario, the incremental cost-effectiveness ratio (ICER) per QALY gained was 9.8 million Japanese yen from the healthcare perspective, but it was 900,000 Japanese yen from the societal perspective, making the program of universal immunization against rotavirus highly cost-effective. Furthermore, the universal immunization program was found to be cost-effective from the societal perspective for any of the previously reported incidence rates of rotavirus-associated hospitalization. Thus, the introduction of the rotavirus vaccine into the childhood immunization schedule and its co-administration with other childhood vaccines will be a cost-effective public health intervention in Japan.
authors.affiliation: Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, and Global Center of Excellence, Nagasaki University, Nagasaki 852-8523, Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Sato
authors.forename: Toyoko
authors.initials: T
authors.lastname: Nakagomi
authors.forename: Osamu
authors.initials: O
authors.lastname: Nakagomi
mesh_terms: D002648:Child; D003362:Cost-Benefit Analysis; D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D017048:Health Care Costs / Q000706:statistics & numerical data; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007564:Japan / Q000453:epidemiology; D008390:Markov Chains; D009313:National Health Programs / Q000191:economics; D019057:Quality-Adjusted Life Years; D012401:Rotavirus / Q000472:pathogenicity; D012400:Rotavirus Infections / Q000453:epidemiology / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000191:economics
chemical_list: D022243:Rotavirus Vaccines